Taiwan President Tsai Ing-wen (L) receives a souvenir during her inspection of a Republic of China Navy (commonly called the Taiwan Navy) fleet in Keelung, Taiwan, on March 8, 2021. (Sam Yeh/AFP via Getty Images)
Taiwanese President Tsai Ing-wen received her first dose of the island’s domestically developed CCP (Chinese Communist Party) virus, commonly known as the novel coronavirus, vaccine on Aug. 23, launching its rollout to the public.
The vaccine, made by Medigen Vaccine Biologics Corp., was given emergency approval by regulators in July using a shortcut that prompted fierce opposition from parts of Taiwan’s medical and scientific community.
Taiwanese regulators bypassed the large-scale, longer-term studies that are typically used to approve vaccines. Instead, they compared the level of antibodies that Medigen’s vaccine was able to generate with that of AstraZeneca’s vaccine, which has been approved by many governments and has undergone the full three stages of clinical trials. The two-dose Medigen protein subunit vaccine uses a piece of the coronavirus to teach the body to mount an immune response.
The decision to give approval based on the new standard prompted an expert from the advisory committee on vaccines to resign. Critics say granting approval before finishing full clinical trials does not provide adequate information on how effective the vaccine is in the real world in protecting from COVID-19, although initial studies may have promising results.
The level of antibodies in the blood is known to correlate with protection from the disease, but scientists do not yet know what the exact level is.
Regulators said Medigen will be required to submit real-world efficacy data within a year of the approval. They said, when approving the vaccine, that data provided by Medigen showed that it produced 3.4 times the level of neutralizing antibodies as the AstraZeneca vaccine.
Tsai received her first dose of the vaccine on Monday morning at a gymnasium at National Taiwan University in Taipei.
As of Aug. 20, 40 percent of Taiwan’s population of 23 million had received at least one dose of a CCP virus vaccine.
The island’s vaccination policy is to prioritize first shots, with only the most high-risk groups initially getting the full two doses, such as medical workers.